anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This trial will include patients who are not candidates for transplantation and above the age of 55. Treatment cycles will include (MP)melphalan (9 mg /sq.m/day d1-4), prednisolone (60 mg/sq.m/d,d1-4) every six weeks for maximum 8 cycles. Patients will be randomised to (MPT) Thalidomide (1:1) 100 mg/day continuously. Cross-over to MPT is allowed if insufficient response is obtained in the MP arm. response will be evaluated every other cycle. At the end of 12 months of treatment patients will be followed until progress and death. Second line treatment is not defined.
BACKGROUND: The term "Overlap Syndrome" (OS) describes the presence of both chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in a single individual. Excessive daytime sleepiness (EDS) is a common symptom of OS shown to be associated with an increased risk of cardiovascular disease (CVD) that could be reduced through exercise. Thus, we propose to investigate a novel exercise intervention in individuals with the EDS-OS phenotype as they are at highest risk of CVD yet have the greatest barriers to exercise.
METHODS: We will conduct a single-site, randomized, two-arm, parallel group-controlled exercise trial in individuals with EDS-OS. The Epworth Sleepiness Scale (ESS) will be assessed at baseline. Individuals with OS and the EDS-OS phenotype (ESS >10) (n = 46) will be randomized to a moderate intensity interval training (MIIT, i.e. intervals of 5 min at 50% VO2peak followed by 3 min of active recovery at 10% VO2peak) or a control group of standard of care. We will investigate if MIIT intervention decreases the risk of CVD in EDS-OS, which will be assessed by: 1) quality of life, measured by the 36-Item Short Form Health Survey; 2) physical activity, measured by daily step counts; and 3) cardiovascular health, assessed as VO2peak, flow-mediated dilation and serum high sensitivity C-reactive protein, lipids, and glucose.
CONCLUSION: Our findings will guide future development and implementation of exercise interventions that could reduce the risk of CVD in the understudied EDS-OS phenotype.
The invention provides an ultrasonic diagnostic apparatus and a diagnosis assisting method. An image analysis unit (28) detects a lesion for each tomographic image. An image analysis unit (28) outputs a position data sequence and a size data sequence indicating temporal changes in the position and size of a lesion in the state in which the lesion is detected. A change rate calculation unit (33) calculates a change rate indicating the degree of temporal change in the tomographic image content. A smoothing unit (34) smoothes the position data sequence and the size data sequence according to the rate of change. A mark is generated based on the smoothed position data sequence and size data sequence.
A system and apparatus (200) relates to a system and apparatus for accurate and secure dispensing of products using an automated dispensing machine, and transmission, processing and analysis of data concerning items dispensed. In one embodiment the system provides the possibility of combined pharmaceutical supply chain management and medication treatment compliance management. More particularly, in one embodiment the present invention may be applied to controlled dispensing of medications, automated replenishment of medications, managing correct dosage and time intervals for patient prescriptions, enabling incentives to encourage higher patient treatment compliance, recording and processing of patient and health care data relating to consumption of medication and related information such as safety, efficacy, patient attitudes and behaviour. The embodiment features a plurality of product dispensing mechanisms (210) referred to as the "Hold/Release" mechanism which has the benefits of high reliability, long service life and low probability of malfunction, and features an integrated RFID antenna (240), which is utilised to ensure the correct product is loaded into the dispenser, resulting in high accuracy of dispensing and inventory management benefits. Dispensing of products only occurs once a set of conditions is satisfied, for example a code corresponding to an electronically entered prescription is entered into a keypad, or an RFID Tagged prescription document is presented to an RFID reader antenna connected to System 200. A Patient ID tag, Healthcare workers ID Tag or other RFID Tagged items can be placed on an RFID antenna connected to System 200 in order to trigger a "transaction". The details are sent to a central server for processing. This process allows for automatic replenishment of medications to the RFID equipped medication storage enclosure at the healthcare site. It also allows for complete logging of data relating to which patient has received the correct dosage at what time, by whom this medication was administered, and correlation with other possible RFID tagged documents.
INTRODUCTION: Patients undergoing pancreaticoduodenectomy for distal cholangiocarcinoma (dCCA) often develop cancer recurrence. Establishing timing, patterns and risk factors for recurrence may help inform surveillance protocol strategies or select patients who could benefit from additional systemic or locoregional therapies. This multicentre retrospective cohort study aimed to determine timing, patterns, and predictive factors of recurrence following pancreaticoduodenectomy for dCCA.
MATERIALS AND METHODS: Patients who underwent pancreaticoduodenectomy for dCCA between June 2012 and May 2015 with five years of follow-up were included. The primary outcome was recurrence pattern (none, local-only, distant-only or mixed local/distant). Data were collected on comorbidities, investigations, operation details, complications, histology, adjuvant and palliative therapies, recurrence-free and overall survival. Univariable tests and regression analyses investigated factors associated with recurrence.
RESULTS: In the cohort of 198 patients, 129 (65%) developed recurrence: 30 (15%) developed local-only recurrence, 44 (22%) developed distant-only recurrence and 55 (28%) developed mixed pattern recurrence. The most common recurrence sites were local (49%), liver (24%) and lung (11%). 94% of patients who developed recurrence did so within three years of surgery. Predictors of recurrence on univariable analysis were cancer stage, R1 resection, lymph node metastases, perineural invasion, microvascular invasion and lymphatic invasion. Predictors of recurrence on multivariable analysis were female sex, venous resection, advancing histological stage and lymphatic invasion.
CONCLUSION: Two thirds of patients have cancer recurrence following pancreaticoduodenectomy for dCCA, and most recur within three years of surgery. The commonest sites of recurrence are the pancreatic bed, liver and lung. Multiple histological features are associated with recurrence.
The present invention relates to a traditional Chinese medicine for treating liver and gallbladder lithiasis and a production method thereof, which belongs to the traditional Chinese medicine preparation. The medicine mainly solves the problem of the recurrence of liver and gallbladder lithiasis. The medicine is composed of the following components by part by weight: 9 to 15 parts of radix bupleuri, 24 to 40 parts of curcuma, 9 to 20 parts of red peony root, 9 to 15 parts of green tangerine peel, 9 to 15 parts of dried tangerine peel, 9 to 15 parts of immature orange fruit, 36 to 60 parts of chicken's gizzard membrane, 6 to 15 parts of banksia rose, 10 to 30 parts of radix et rhizoma rhei from Sichuan of China, 20 to 30 parts of corydalis tuber, 20 to 30 parts of lonicera, 36 to 60 parts of potassium nitrate, 18 to 30 parts of alum, 9 to 15 parts of fructus aurantii, 60 to 100 parts of talcum levigating, and 12 to 20 parts of licorice root. The raw medicinal materials are processed and respectively ground into fine powder to be evenly mixed, and consequently, the capsule preparation or the pill preparation is prepared according to the metering. The medicine fundamentally eliminates the lithiasis forming factors and fully regulates the body and the motivation so that lithiasis can not recur, and pain brought by lithiasis is eliminated for forever. Thus, pain of the patients with liver and gallbladder lithiasis is eradicated at the earliest date, and the patients pull through. The medicine is mainly used for treating liver and gallbladder lithiasis.
OBJECTIVES: To test whether intraoperative ultrasound can reduce the incidence of early and late complications following surgical removal of products of conception.
DESIGN: This was a prospective, multicentre, randomised, open clinical trial to assess feasibility. It was performed in two University Teaching hospitals in the West Midlands, England. The population consisted of women aged 16 years or over who were referred for surgical management of miscarriage. Patients were randomised to surgical management of miscarriage with either continuous intraoperative ultrasound or without intraoperative ultrasound. Process outcomes included the proportion of eligible women screened and proportion of eligible women randomised, attrition rates, evaluation of outcome measurement tools and acceptability. The primary clinical outcome was a composite outcome of unsuccessful procedure or a complication.
RESULTS: Fifty-nine women requiring surgical management of miscarriage were randomised. The conversion rate for entry into the trial was 59/79(75 %; 95 %CI = 64-84 %). The composite clinical outcome was attained in 5/27(19 %) patients who had surgery without ultrasound and 7/28(25 %) patients who had surgery with ultrasound (RR = 0.74;95 %CI = 0.26, 2.10). When we excluded the patients that could not attend their hysteroscopy appointment, due to COVID-19 pandemic, 5/27(19 %) of patients who had surgery without ultrasound and 5/25(20 %) of patients who had surgery with ultrasound attained the composite clinical outcome (RR = 0.93;95 %CI = 0.30, 2.90).
CONCLUSIONS: This multicentre pilot study showed that a large RCT comparing surgical management of miscarriage with and without intraoperative ultrasound is feasible.
Postoperative cognitive dysfunction (POCD) is a common complication following surgery, adversely impacting patients' recovery, increasing the risk of negative outcomes, prolonged hospitalization, and higher mortality rates. The N-methyl-D-aspartate (NMDA) receptor, crucial for learning, memory, and synaptic plasticity, plays a significant role in the development of POCD. Various perioperative factors, including age and anesthetic use, can reduce NMDA receptor function, while surgical stress, inflammation, and pain may lead to its excessive activation. This review consolidates preclinical and clinical research to explore the intricate relationship between perioperative factors affecting NMDA receptor functionality and the onset of POCD. It discusses the influence of aging, anesthetic administration, perioperative injury, pain, and inflammation on the NMDA receptor-related pathophysiology of POCD. The comprehensive analysis presented aims to identify effective treatment targets for POCD, contributing to the improvement of patient outcomes post-surgery.
This group will have a 20% reduction in caloric intake and meeting schedule, and physical activity goal similar to the In-Person group. However, the remote arm intervention will be delivered via video conferencing.
Contact assemblies, electroplating machines with contact assemblies, and methods for making contact assemblies that are used in the fabrication of microelectronic workpieces. The contact assemblies can be wet-contact assemblies or dry-contact assemblies. A contact assembly for use in an electroplating system can comprise a support member and a contact system coupled to the support member. The support member, for example, can be a ring or another structure that has an inner wall defining an opening configured to allow the workpiece to move through the support member along an access path. In one embodiment, the support member is a conductive ring having a plurality of posts depending from the ring that are spaced apart from one another by gaps. The contact system can be coupled to the posts of the support member. The contact system can have a plurality of contact members projecting inwardly into the opening relative to the support member and transversely with respect to the access path. The contact members can comprise electrically conductive biasing elements, such as fingers, that have a contact site and a dielectric coating covering at least a portion of the biasing elements. The contact members can also have a raised feature configured to engage the seed-layer on the workpiece for conducting the current to the seed-layer.
OBJECTIVES: The objectives of this study are to study the risk of developing cardiac arrhythmia and its subtypes over time in patients with systemic sclerosis (SSc), to assess potential risk factors for arrhythmia in SSc and to explore whether arrhythmia is associated with mortality.
METHODS: We used nationwide Swedish registers to identify patients with incident SSc 2004-2019 and matched general population comparators (1:10). The primary outcome was incident arrhythmia. Follow-up started at the date of SSc diagnosis and ended at the primary outcome, death, emigration or 31 December 2019. We estimated the incidence of arrhythmia overall and stratified by subtype and explored the relative risk in relation to time since diagnosis using flexible parametric models. We used Cox regression to study risk factors for arrhythmia and the association of arrhythmia with mortality.
RESULTS: We identified 1565 patients and 16 009 comparators. The overall incidence of arrhythmia was 255 (95% CI 221 to 295) and 119 (95% CI 112 to 127) per 10 000 person years in patients with SSc and comparators, respectively, corresponding to an IRR of 2.1 (95% CI 1.8 to 2.5). The greatest hazard difference between patients with SSc compared with the comparators was seen in the first year of follow-up (HR for arrhythmia 3.0; 95% CI 2.3 to 3.8). Atrial fibrillation and flutter were the most common arrhythmia subtypes. Male sex, index age and pulmonary arterial hypertension were significant risk factors for arrhythmia in SSc. Incident arrhythmia was significantly associated with mortality (HR 2.2; 95% CI 1.6 to 3.0).
CONCLUSION: SSc is associated with higher incidence of cardiac arrhythmia compared with general population. Arrhythmia seems to be an early manifestation of SSc and is associated with higher mortality.
Lysergic acid diethylamide (LSD) is the prototype hallucinogen used recreationally worldwide. In the 50-70s, LSD was also used to study psychotic-like states in normals ("model psychosis") and in "psycholytic psychotherapy". Potential research and therapeutic uses of LSD are now re-recognized and may include its use in brain research, treatment of cluster headache, and aid in psychotherapy and in terminally ill patients. A better and contemporary understanding of the pharmacology of LSD is important in the light of its widespread recreational, and potential scientific and therapeutic uses. The study has no primary therapeutic intentions but aims for a solid account of the clinical pharmacological characteristics of the drug. To characterize the acute physiological, psychological, endocrine, and pharmacological response to the administration of a single dose of LSD in healthy subjects the investigators use a randomized double-blind placebo-controlled cross-over design with two experimental sessions. Subjects will participate in a placebo and a LSD session. Subjective and cardiovascular responses will be repeatedly assessed throughout the experiments and plasma samples are collected for pharmacokinetics and endocrine measurements.Additionally long-term psychological changes associated with the LSD experience are assessed.
Clinical studies of lisinopril in patients with hypertension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience in this population has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

In the ATLAS trial of lisinopril in patients with congestive heart failure, 1,596 (50%) were 65 and over, while 437 (14%) were 75 and over. In a clinical study of lisinopril in patients with myocardial infarctions 4,413 (47%) were 65 and over, while 1,656 (18%) were 75 and over. In these studies, no overall differences in safety or effectiveness were observed between elderly and younger patients, and other reported clinical experiences has not identified differences in responses between the elderly and younger patients (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Heart Failure and CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Acute Myocardial Infarction ).

Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Pharmacokinetic studies indicate that maximum blood levels and area under the plasma concentration time curve (AUC) are doubled in older patients (see CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism ).

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Evaluation of patients with hypertension, congestive heart failure, or myocardial infarction should always include assessment of renal function (see DOSAGE AND ADMINISTRATION ).
The invention relates to a traditional Chinese medicine composition for treating helicobacter pylori and a preparation method thereof. The medicine composition has better inhibiting and killing effects on helicobacter pylori. The formula of the invention comprises the following components: 10-20 parts of radix bupleuri, 5-10 parts of radix scutellariae, 10-16 parts of dandelion, 15-20 parts of oldenlandia diffusa, 10-15 parts of barbed skullcap herb, 10-30 parts of fried hawthorn fruit, 10-15 parts of fried medicated leaven, 20-30 parts of fried malt, 15-25 parts of fructus aurantii, 10-15 parts of fritillary bulb, 20-30 parts of cuttlebone, 20-30 parts of radix codonopsitis, 10-15 parts of fried bighead atractylodes rhizome, 20-30 parts of poria cocos, 10-15 parts of costustoot, 6-10 parts of fructus amomi, 3-6 parts of clove, 5-10 parts of liquorice and the like. At present, western medicine triple or quadruple therapy is mostly adopted for infection of helicobacter pylori. Although the curative effect is remarkable, the traditional Chinese medicine is difficult to radically eradicate, and the liver and kidney functions are also affected by frequent administration of antibiotics. Compared with the invention, the invention takes strengthening body resistance and consolidating constitution as rigidity, strengthening spleen and harmonizing stomach, soothing liver and regulating qi, clearing stomach heat, relieving hyperacidity and relieving pain. Has remarkable treatment effect on digestive tract diseases caused by helicobacter pylori, stable efficacy, lasting effect, low drug price and no toxic or side effect after long-term administration.
Aortic stenosis is the most clinically important valvular heart disease in the elderly, with severe aortic stenosis accounting for about 3.4%-5% of elderly patients. Patients with chest pain, congestive heart failure, or syncope who do not undergo surgical intervention have a poor prognosis, with a 1-year mortality rate as high as 50%. However, the high surgical risk of surgical valve replacement for elderly patients with multiple underlying diseases limits the use of surgical valve replacement, and the prognosis of high-risk surgical patients is poor. The PARTNER series of studies and the US CoreValve high-risk studies confirm that perioperative and postoperative adverse events in patients undergoing TAVR in surgical high-risk patients are comparable to those in surgical valve replacement. With technological advances, the indications for TAVR have been expanded from surgical high-risk to low to moderate-risk populations. Based on the PARTNER 3 and Evolut Low Risk studies, FDA approved the use of TAVR to treat low surgical risk patients with symptomatic severe aortic stenosis. Recently, TAVR has also been expanded to patients with aortic valve regurgitation.

With a population of 1.4 billion, China has a large number of patients with aortic valve disease, but the TAVR program was launched in 2010. No large-scale TAVR studies are available to validate the efficacy and safety of TAVR in the Chinese population. The morphological characteristics of valves in our patients bring great challenges to the operation and application of TAVR. However, through the efforts of Chinese experts and scholars, TAVR technology in China has developed rapidly, and various domestic valves with independent intellectual property have been marketed, bringing new opportunities for the promotion and application of TAVR in China. Domestic valves have been designed for the Chinese aortic valve anatomy, which is theoretically more suitable for the Chinese population. However, the efficacy and safety of these valves still need to be further confirmed in large clinical studies.

This multi-center registry study aims to evaluate the safety and efficacy of all post-marketing transcatheter valves in Chinese patients with aortic valve disease mixed. Investigators will collect baseline and procedural data, and evaluate the short-, mid-, and long-term clinical outcomes of TAVR in a large real-world population.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to pediatrics and pulmonology, and can be used for the treatment and prophylaxis in children of recurrent bronchitis associated with exposure to fine dust. In the period of incomplete remission or remission, a combined medical and physiotherapeutic treatment is carried out therefor. Starting from the first day of treatment, Ambroxol drug is administered orally during a meal with a small amount of liquid in an age dose from 3 years to 6 years – 7.5 mg 3 times a day, from 6 years old to 12 years old – 15 mg 2 times a day, over 12 years old – 15 mg 3 times a day in a course of 7 days, starting from the first day. Hypoxen drug is also administered orally before or during meals, 1 capsule 2 times a day for 21 days. Starting from the eleventh day of treatment, the Broncho-Munal drug is administered orally in the form of capsules in the morning on an empty stomach in the age dose from 3 to 12 years – 3.5 mg, from 12 years – 7 mg in a course of 10 days. As a physiotherapeutic treatment, simultaneously with the drug treatment, starting from the first day of treatment, an apparatus physiotherapy method is carried out, namely, low-intensity magnetic therapy with a course of 10–15 procedures. In addition, starting from the second day of drug administration, a complex of physiotherapeutic methods is carried out, including halotherapy in combination with aeroionotherapy course of 10–12 procedures each.EFFECT: method ensures shortening the periods of exacerbations and reducing the frequency of relapses, reducing the frequency of complications due to the positive dynamics of clinical symptoms and respiratory function as a result of detoxification and activation of anti-inflammatory, antihypoxic, immunomodulating and metabolic action, restoration of homeostasis and natural immunological resistance, due to pronounced positive synergism of the components of the proposed comprehensive treatment.1 cl, 1 ex, 3 tbl